1. Inicio
  2. Carlos Andrés Ceballos Garzón
Carlos Andrés Ceballos Garzón
  • carlos.ceballos@urosario.edu.co

Carlos Andrés Ceballos Garzón

  • Profesor principal de carrera, Escuela de Medicina y Ciencias de la Salud , Universidad del Rosario - 2005
  • Investigador, Grupo de Investigación de Estudios en Microbiología Traslacional y Enfermedades Emergentes - MICROS , Instituto de Medicina Traslacional - IMT - 2000

Áreas de investigación

  • Fungal infections
  • Infectious diseases
  • Medical Microbiology
  • Medical mycology
  • Microbiology
  • Molecular biology
  • Perfil
  • Formación Académica
  • Publicaciones
  • Proyectos

Perfil

Perfil Profesional

  • Prof. Andrés Ceballos is a medical laboratory scientist and microbiologist with dual doctorates in mycology and Biology & Health. His academic background includes postdoctoral research in molecular epidemiology at Université Clermont Auvergne and medical mycology at Université de Nantes in France. Prof. Ceballos-Garzón has garnered recognition for his research on pathogenic fungi, particularly Candida species, contributing to the understanding of fungal resistance mechanisms. He is currently a professor at the School of Medicine at Universidad del Rosario in Bogotá, Colombia, and formerly headed BIOASTER's medical mycology laboratory in Lyon, France, focusing on innovative diagnostic and therapeutic approaches against fungal infections. His faculty member interests include epidemiology, drug resistance, and tolerance to antifungal drugs. His expertise encompasses genomic, proteomic, and phenotypic analyses. Prof. Ceballos-Garzón’s prolific scientific output includes numerous high-impact publications and presentations at international conferences. His accolades include the prestigious Eiffel Excellence Scholarship and multiple doctoral training scholarships. He actively collaborates with global research institutions and is a member of several esteemed scientific societies, including the Clinical & Laboratory Standards Institute, where he serves on the development committee for broth dilution documents for yeasts (M27) and moulds (M38). He is also a member of the Colombian Association of Infectious Diseases.
  • Formación Académica

    Formación Académica Complementaria

  • 2025, Herramientas de Ia para la Investigación: Aplicaciones Prácticas Fecha 2, Desarrollo profesoral-Universidad del Rosario
  • Publicaciones

    Publicaciones

  • artículos académico

    • Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens
      2026-9-1
    • Wickerhamomyces anomalus Fungemia during Healthcare-Associated Outbreak, Pereira, Colombia, 2025
      2026-6-1
    • Wickerhamomyces anomalus Fungemia during Healthcare-Associated Outbreak, Pereira, Colombia, 2025
      2026-6-1
    • Wild-type MIC distributions and Epidemiological Cut-off Values for Ibrexafungerp, Manogepix, and Rezafungin against WHO Fungal Priority Pathogens
      2026-6-1
    • Outbreak of Wickerhamomyces anomalus (formerly Candida pelliculosa) Bloodstream Infections, Venezuela, 2022-2023 1
      2026-5-26
    • Outbreak of Wickerhamomyces anomalus (formerly Candida pelliculosa) Bloodstream Infections, Venezuela, 2022-20231
      2026-5-26
    • Diagnostic and therapeutic capacity for fungal infections in Colombia: An ESCMID-EFISG nationwide multicenter assessment of mycological healthcare
      2026-1-1
    • First report of Lodderomyces elongisporus in France: Tracing from accidental skin contact to mobile device contamination
      2026-1-1
    • Comparative genomics of Candida albicans isolates from Bogotá, Colombia
      2026
    • Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains
      2025-6-1
    • Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: A comparative study using CLSI, EUCAST and Sensititre YeastOne methods
      2025-4-1
    • First report of Candida (Candidozyma) auris infections in a human and a dolphin from the Dominican Republic: A One health perspective
      2025-12-1
    • Applying targeted gene hybridization capture to viruses with a focus to SARS-CoV-2
      2024-2-1
    • The Mortality Attributable to Candidemia in C. auris Is Higher than That in Other Candida Species: Myth or Reality?
      2023-4-1
    • Antimicrobial Resistance Profiles of Staphylococcus Isolated from Cows with Subclinical Mastitis: Do Strains from the Environment and from Humans Contribute to the Dissemination of Resistance among Bacteria on Dairy Farms in Colombia?
      2023-11-1
    • Proteomics and Genetic Approaches Elucidate the Circulation of Low Variability Staphylococcus aureus Strains on Colombian Dairy Farms
      2023-11-1
    • Emergence and circulation of azole-resistant C. albicans, C. auris and C. parapsilosis bloodstream isolates carrying Y132F, K143R or T220L Erg11p substitutions in Colombia
      2023-1-1
    • Evaluation of Anti-Candida Potential of Piper nigrum Extract in Inhibiting Growth, Yeast-Hyphal Transition, Virulent Enzymes, and Biofilm Formation
      2022-8-1
    • Prototheca Infections and Ecology from a One Health Perspective
      2022-5-1
    • Head‐to‐head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testing
      2022-4-1
    • CRISPR-Cas9 approach confirms Calcineurinresponsive zinc finger 1 (Crz1) transcription factor as a promising therapeutic target in echinocandin-resistant Candida glabrata
      2022-3-1
    • Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata
      2022-3-1
    • Chimeric Peptides Derived from Bovine Lactoferricin and Buforin II: Antifungal Activity against Reference Strains and Clinical Isolates of Candida spp.
      2022-11-1
    • Phages, anti-CRISPR proteins, and drug-resistant bacteria: What do we know about this triad?
      2022-1-1
    • The Combination of Iron and Copper Increases Pathogenicity and Induces Proteins Related to the Main Virulence Factors in Clinical Isolates of Cryptococcus neoformans var. grubii
      2022-1-1
    • Palindromic Peptide LfcinB (21-25)Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida
      2020-6-30
    • Development and validation of an in-house library of colombian candida auris strains with maldi-TOF MS to improve yeast identification
      2020-6-1
    • Impact of calmodulin inhibition by fluphenazine on susceptibility, biofilm formation and pathogenicity of caspofungin-resistant Candida glabrata
      2020-5-1
    • Cerebral phaeohyphomycosis caused by Alternaria spp.: A case report
      2020-3-1
    • In-house protocol and performance of MALDI-TOF MS in the early diagnosis of bloodstream infections in a fourth-level hospital in Colombia: Jumping to full use of this technology
      2020-12-1
    • Comparison between MALDI-TOF MS and MicroScan in the identification of emerging and multidrug resistant yeasts in a fourth-level hospital in Bogotá, Colombia
      2019-5-23
    • First report of sporadic cases of Candida auris in Colombia
      2018-4-1
    • Zygomycete Fungi Infection in Colombia: Literature Review
      2018-12-1
    • Characterising atypical Candida albicans clinical isolates from six third-level hospitals in Bogotá, Colombia
      2015-10-5
  • cartas

    • In vitro evaluation of Ibrexafungerp against clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii
      2025-12-1
    • Invasive infections with multidrug-resistant yeast Candida auris, Colombia
      2017-1-1
  • prensa y medios

    • The fungus Candida Auris can be contracted in swimming pools, but there is no need for alarm.
      2024
    • Another sign to stop the Candida auris fungus.
      2023
    • Studies in the Area of Drug Resistance Reported from Universite Clermont Auvergne (Phages, anti-CRISPR proteins, and drug-resistant bacteria: what do we know about this triad?)
      2022
  • Proyectos

    Investigador Principal

  • Comprehensive Analysis of Antifungal Susceptibility, Epidemiology, Resistance Mechanisms, and Molecular Biology in Emerging and Clinically Relevant Human Fungal Pathogens 2025-01-01 - 2027-12-31
  • Detección de resistencia antifúngica en Candida spp. mediante MALDI-TOF MS: integración con mecanismos genéticos para un diagnóstico rápido 2026-11-01 - 2027-05-31
  • Mejore su perfil